Idera Pharmaceuticals

Idera Pharmaceuticals is a clinical-stage patient-focused biopharmaceutical company developing novel nucleic acid therapeutic approaches for the treatment of certain cancers and rare diseases. Idera’s immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while our third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA. Our talented scientists are passionate about what matters most—people. It’s what motivates the Idera team, and it’s why we’re laser-focused on translating our pioneering nucleic acid science and technologies into medicines that will target diseases unlike any other treatment available.
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
1989
Size (employees)
62 (est)
Idera Pharmaceuticals was founded in 1989 and is headquartered in Cambridge, US

Key People at Idera Pharmaceuticals

Sudhir Agrawal

Sudhir Agrawal

Chief Executive Officer and President, Board of Directors
Louis J. Arcudi

Louis J. Arcudi

Senior Vice President of Operations, Chief Financial Officer, Treasurer, and Secretary
Robert D. Arbeit

Robert D. Arbeit

Vice President, Clinical Development
Timothy M. Sullivan

Timothy M. Sullivan

Vice President, Development Programs and Alliance Management
James Geraghty

James Geraghty

Chairman of the Board & Board of Directors

Idera Pharmaceuticals Office Locations

Idera Pharmaceuticals has offices in Cambridge and Exton
Cambridge, US (HQ)
167 Sidney Street
Exton, US
212 505 Eagleview Blvd

Idera Pharmaceuticals Data and Metrics

Idera Pharmaceuticals Financial Metrics

Idera Pharmaceuticals's revenue was reported to be $249 k in FY, 2015 which is a 241% increase from the previous period.
$, USD

Revenue (FY, 2015)

249 k

Revenue growth (FY, 2014 - FY, 2015), %

241%

Net income (FY, 2015)

(48.6 m)

Market capitalization (22-Jun-2017)

258 m

Closing share price (22-Jun-2017)

1.7

Cash (31-Dec-2016)

80.7 m
Idera Pharmaceuticals's current market capitalization is $258 m.
$, USDFY, 2013FY, 2014FY, 2015

Revenue

47 k73 k249 k

Revenue growth, %

55%241%

Net Income

(18.2 m)(38.6 m)(48.6 m)
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

26.3 m20 m26.6 m80.7 m

Inventories

874 k1.2 m3.1 m2 m

Current Assets

30.3 m42.4 m63.2 m111 m

PP&E

90 k1.3 m1.7 m1.9 m

Total Assets

36.9 m51.4 m92.3 m113.2 m

Accounts Payable

904 k2.5 m1.2 m556 k

Current Liabilities

4.4 m7 m6.8 m9.4 m

Additional Paid-in Capital

434.3 m494.9 m583.7 m641.7 m

Retained Earnings

(412.9 m)(451.5 m)(500.1 m)(538.5 m)

Total Equity

32.5 m43.4 m83.6 m103.3 m

Financial Leverage

1.1 x1.2 x1.1 x1.1 x
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(18.2 m)(38.6 m)(48.6 m)(38.4 m)

Depreciation and Amortization

137 k206 k488 k656 k

Inventories

(676 k)(329 k)(1.9 m)1.1 m

Cash From Operating Activities

(17.1 m)(31.3 m)(43 m)(28.2 m)

Purchases of PP&E

(9 k)(1.1 m)(727 k)(408 k)

Cash From Investing Activities

(9.3 m)(20.6 m)(33.4 m)31.4 m

Short-term Borrowings

(4 k)(5 k)(10 k)(7 k)

Dividends Paid

(1.1 m)(798 k)(798 k)(798 k)

Cash From Financing Activities

42.7 m45.6 m83 m50.9 m
Y, 2016

Financial Leverage

1.1 x

Idera Pharmaceuticals Market Value History

Idera Pharmaceuticals Company Life and Culture

You may also be interested in